Cite
Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021;9(11):1288-1298doi: 10.1016/S2213-2600(21)00167-3.
Rabe, K. F., Celli, B. R., Wechsler, M. E., Abdulai, R. M., Luo, X., Boomsma, M. M., Staudinger, H., Horowitz, J. E., Baras, A., Ferreira, M. A., Ruddy, M. K., Nivens, M. C., Amin, N., Weinreich, D. M., Yancopoulos, G. D., & Goulaouic, H. (2021). Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. The Lancet. Respiratory medicine, 9(11), 1288-1298. https://doi.org/10.1016/S2213-2600(21)00167-3
Rabe, Klaus F, et al. "Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial." The Lancet. Respiratory medicine vol. 9,11 (2021): 1288-1298. doi: https://doi.org/10.1016/S2213-2600(21)00167-3
Rabe KF, Celli BR, Wechsler ME, Abdulai RM, Luo X, Boomsma MM, Staudinger H, Horowitz JE, Baras A, Ferreira MA, Ruddy MK, Nivens MC, Amin N, Weinreich DM, Yancopoulos GD, Goulaouic H. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021 Nov;9(11):1288-1298. doi: 10.1016/S2213-2600(21)00167-3. Epub 2021 Jul 21. PMID: 34302758.
Copy
Download .nbib